2. About Us…

3. About Us…

4. About Us…

5. About Us…

6. About Us…

7. Regulatory Approvals LOCATION DOSAGE FORM APPROVALS GOA I
TABLETS, CREAMS & ONITMENTS
USFDA
EU / UK- GMP (Restricted)
UKRAINE
IVORY COAST
GOA II
EU - GMP (Restricted)
TGA, AUSTRALIA
ZIMBABWE
NIGERIA
GOA III
TABLETS
EU - GMP
WALUJ
BADDI I
TABLETS, LIQUID ORALS & TOOTHPASTES
EU - GMP & EU / UKMHRA
BADDI III
TABLETS & CAPSULES
UKMHRA
PATALGANGA
API's
USFDA, EDQM
KILOLAB

8. Business Model INDIAN BUSINESS International Business Allied Services
Branded Generics
Active Pharmaceutical Ingredients (APIs) (Captive Consumption & Supply to end users)
INDIAN
BUSINESS
Regulated Markets Generics CRAMS
Emerging Markets Branded Generics
International
Business
AnaCipher - CRO for BA / BE Studies
- Analytical Services
Xtend Industrial Designers and Engineers
Allied
Services

9. Indian Formulation Business
TOP BRANDS
FEBREX PLUS
CYCLOPAM
SENSODENT K
OXIPOD
CITAL
ATM
CLOBEN G
SENSOFORM
SENSODENT KF
KARVOL PLUS
Marketing Divisions
Main Doctor Specialties
INDOCO
Multi Specialty Division
SPADE
GP, CP, ENT, Pediatrician
Warren ACE
Dentists
Warren NXGen
Dentists / Super specialties within Dentistry
SPERA
Gynecologists, General Practitioners
INDOCO FOCUS
Consulting Physicians / Endocrinology
INDOCO CND
Cardiologists, Diabetologists, Consulting Physicians
Warren EXCEL / VISION
Ophthalmologists
INSTITUTION
Private Corporate Hospitals & Govt. Institutions

10. Indian Business - Growth Drivers
Rising income levels, rapid urbanization, changing lifestyle, rapid expansion in healthcare insurance sector, demand for quality healthcare services
Brand building and focus on sub-chronic segment / mass specialities
Focus on legacy Brands belonging to growth market
Further, penetration in Northern and Eastern Regions to achieve regional balance / increase overall productivity
New Products introductions
(Around 10 products including brand extensions every year)
Focus on developing sustainable prescription support from Doctors Specialties
Significant API contribution both for captive consumption and external sales, with expanded product basket and services

11. International Business
Revenue of
` 161 Crs in
Revenue contribution
(Europe 46%, USA 11%,
SA & ANZ 12%)
CRAMS, FDF, APIs
MAs / Dossier
Out-Licensing
Regulated Markets
( 69% of
Exports)
` 72 Crs in
Revenue Contribution
(Africa 14%, Asia 4%,
FWA 10%, Latam & Others 3% )
Promotion of Branded
Generics through
Distributors
Emerging Markets
( 31% of

12. International Business - Growth Drivers
Partnerships and alliances
Niche Product pipeline in Ophthalmic / Injectable space in addition to Solid Orals
Regulatory approvals from countries including US / Europe for manufacturing facilities and products
Own filing of ANDAs and Dossiers
Planned shift from CRAMS to supplies against own dossiers / marketing authorizations in regulated markets
Creation of own Intellectual Property through Patents and Trademarks
NDDS and new platform technologies for future commercial exploitation

13. Financials Particulars Quarter Ended Full Year 31.03.19 31.03.18
Net Revenues
245.0
258.9
941.4
1017.3
Profit After Tax
11.6
20.5
(2.8)
41.2
% to Net Sales
4.7
7.9
(0.3)
4.0
EBIDTA
28.5
49.4
76.7
134.9
19.1
8.1
13.3
Operating Profit
17.6
38.5
36.1
97.1
7.2
14.9
3.8
9.5
Earnings per Share (EPS) Face Value ( ` 2/-)
1.26
2.22
(0.31)
4.47

14. Safe Harbor…
This presentation may include certain forward – looking statements and information that involve risks, uncertainties and assumptions based on current expectations, within the meaning of applicable laws and regulations. Forward – looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects” and similar expressions. Actual results could differ materially from those projected in forward looking statements and the company does not guarantee realization of these statements. Any forward looking statement or information contained in this presentation speaks only as of the date of the statements. The company also disclaims any obligation to revise any forward looking statements.
No part of this presentation may be reproduced, quoted or circulated without the prior approval from Indoco Remedies Limited.

15. Thank You